Elutia inc. ELUT.US Overview
ELUT AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
ELUT Current Performance
2.53%
Elutia inc.
1.60%
Avg of Sector
0.32%
S&P500
ELUT Key Information
ELUT Revenue by Segments
Browsing restrictions can be lifted for a fee.
ELUT Net Income
Browsing restrictions can be lifted for a fee.
ELUT Cash Flow
Browsing restrictions can be lifted for a fee.
ELUT Profit Margin
Browsing restrictions can be lifted for a fee.
ELUT PE Ratio River
Browsing restrictions can be lifted for a fee.
ELUT Financial Forecast
Browsing restrictions can be lifted for a fee.
ELUT Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
ELUT Profile
Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
Price of ELUT
ELUT FAQ
When is ELUT's latest earnings report released?
The most recent financial report for Elutia inc. (ELUT) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ELUT's short-term business performance and financial health. For the latest updates on ELUT's earnings releases, visit this page regularly.
What is the operating profit of ELUT?
According to the latest financial report, Elutia inc. (ELUT) reported an Operating Profit of -7.92M with an Operating Margin of -131.38% this period, representing a growth of 6.57% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is ELUT's revenue growth?
In the latest financial report, Elutia inc. (ELUT) announced revenue of 6.03M, with a Year-Over-Year growth rate of -9.92%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does ELUT have?
As of the end of the reporting period, Elutia inc. (ELUT) had total debt of 35.25M, with a debt ratio of 0.9. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does ELUT have?
At the end of the period, Elutia inc. (ELUT) held Total Cash and Cash Equivalents of 17.36M, accounting for 0.44 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does ELUT go with three margins increasing?
In the latest report, Elutia inc. (ELUT) did not achieve the “three margins increasing” benchmark, with a gross margin of 40.7%%, operating margin of -131.38%%, and net margin of -65.2%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess ELUT's profit trajectory and future growth potential.
Is ELUT's EPS continuing to grow?
According to the past four quarterly reports, Elutia inc. (ELUT)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.1. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of ELUT?
Elutia inc. (ELUT)'s Free Cash Flow (FCF) for the period is -9.16M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 244.84% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of ELUT?
The latest valuation data shows Elutia inc. (ELUT) has a Price-To-Earnings (PE) ratio of -1.95 and a Price/Earnings-To-Growth (PEG) ratio of 0.1. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.